RecruitingCardiovascular Disease
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Eligible age
35–80 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Sponsor: Amgen
You may qualify if…
- ✓ Age 35 to ≤ 80 years.
- ✓ Lp(a) ≥ 200 nmol/L during screening.
- ✓ Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
- ✓ History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary intervention.
You may not qualify if…
- ✕ History of coronary artery bypass graft (CABG).
- ✕ Moderate to severe renal dysfunction.
- ✕ Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening.
- ✕ History of hemorrhagic stroke.
- ✕ History of major bleeding disorder.
- ✕ Planned cardiac surgery or arterial revascularization.
- ✕ Severe heart failure.
- ✕ Current, recent, or planned lipoprotein apheresis.
Where it's recruiting
Connecticut
Bridgeport
Florida
Jacksonville
Kansas
Overland Park
Maryland
Bowie
Pennsylvania
Philadelphia
Texas
Humble
Source: ClinicalTrials.gov · NCT07293260 · last updated 2026-04-16